

**Hikma Finance USA LLC**  
**Publication of Offering Circular**

7 July 2025

Hikma Finance USA LLC (the "**Issuer**") announces today that it has published an offering circular dated 7 July 2025 (the "**Offering Circular**") in connection with the issuance of US 500,000,000 5.125 per cent. Guaranteed Notes due 2030 (the "**Notes**") guaranteed by Hikma Pharmaceuticals PLC.

The Notes are expected to be admitted to trading on the International Securities Market of the London Stock Exchange on or about 9 July 2025.

The Offering Circular is available for viewing.

To view the Offering Circular please paste the following URL into the address bar of your browser:

[http://www.ms-pdf.londonstockexchange.com/ms/9905P\\_1-2025-7-7.pdf](http://www.ms-pdf.londonstockexchange.com/ms/9905P_1-2025-7-7.pdf)

**Enquiries and Investor Relations**

Susan Ringdal  
EVP, Strategic Planning and Global Affairs  
+44 (0) 20 7399 2760 / +44 7776 477050

**LEI:** 213800BU7YH2WTM1QL87

**Regulated Information Classification:** Additional regulated information required to be disclosed under the laws of a Member State

**DISCLAIMER - INTENDED ADDRESSEES**

Please note that the information contained in the Offering Circular may be addressed to and/or targeted at persons who are residents of particular countries (specified in the Offering Circular) only and is not intended for use and should not be relied upon by any person outside these countries and/or to whom the offer contained in the Offering Circular is not addressed. Prior to relying on the information contained in the Offering Circular, you must ascertain from the Offering Circular whether or not you are one of the intended addressees of the information contained therein.

Your right to access this service is conditional upon complying with the above requirement.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [ms@seg.com](mailto:ms@seg.com) or visit [www.ms.com](http://www.ms.com).

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

CIRPKOBDFBKKNOK